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Abstract 
Although many studies have shown that patients with autoimmune disease present a 
hypoactive hypothalamic-pituitary-adrenal axis (HPA), controversial results have been 
described. Our objective was to study HPA axis activity in women with autoimmune disease 
compared to healthy women. Therefore, we analyzed salivary cortisol over the course of a 
day, and hair cortisol concentrations from the three preceding months, from 65 women 
divided into two groups: healthy women (n = 30), with a mean age of 44.70 ± 11.65 years; 
and women with autoimmune disease (n = 35), with a mean age of 48.26 ± 9.04 years. The 
latter group comprises women with systemic lupus erythematosus (SLE), Sjögren’s syndrome 
(SS), and systemic sclerosis (SSc). Perceived stress and psychopathological symptomatology 
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were also evaluated. Autoimmune disease group scored higher on the somatization subscale 
SCL-90-R and lower on the anxiety subscale than the control group. Regarding HPA axis 
activation, the area under curve for cortisol levels during the day was higher for the 
autoimmune disease group. In addition, higher cortisol levels in hair were found in the group 
with autoimmune disease. Our findings show greater short and long-term HPA axis activity in 
women with autoimmune disease than in healthy women. 
Keywords: stress, cortisol, HPA axis, systemic lupus erythematosus, Sjögren’s syndrome, 
systemic sclerosis 
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Introduction 
 The main systemic autoimmune diseases are characterized largely by affecting 
multiple organs and systems in a single patient, by their unknown etiology, and by periods of 
disease aggravation alternating with periods of disease inactivity (Jiménez-Alonso et al., 
2011). One of the changes seen in these patients is altered activity of the HPA axis (Tzioufas 
et al., 2008). The hypothalamic-pituitary-adrenal axis (HPA) axis plays an important role in 
modulating autoimmune activity by release of glucocorticoids (Charmandari et al., 2005; 
Heesen et al., 2007), hormones secreted in response to stress (McEwen, 2000). Psychological 
stress is considered one of the main causes for the onset and aggravation of symptoms of 
various autoimmune diseases (McCray and Agrawal, 2001; Johnson et al., 2006; Peralta-
Ramírez, et al., 2004; Stojanovich and Marisavljevich, 2008). 
 Cortisol, the main hormone produced in response to stress, has been widely used as an 
HPA axis activity biomarker, and elevated levels of cortisol have important physical and 
psychological consequences. Traditionally, saliva, blood, and urine analyses are conducted to 
establish the amount of cortisol secreted at a precise time within the past 24 hours. However, 
a new procedure has recently been developed using the patient’s hair to provide information 
regarding stress exposure from days up to months (Meyer and Novak, 2012). Hair cortisol is 
considered by some to be an objective and retrospective measure of chronic stress (Gow et al., 
2010). Furthermore, the use of hair avoids the variability of cortisol levels in fluids associated 
to individual and environmental characteristics, study procedures (Wolfram et al., 2013), the 
time of day (Adam et al., 2006), and food consumption (Gibson et al., 1999). 
 No consensus has been reached regarding HPA regulation in autoimmune diseases. 
Some studies show that the psychological stress that patients with autoimmune disease 
experience causes hypoactivity of the HPA axis (Delevaux et al., 2013; Shalimar et al., 2006; 
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Silverman and Sternberg, 2012; Van der Goes et al., 2011). However, Finan and Zautra 
(2013) did not observe that daily stressors or worries influence the cortisol levels of patients 
with rheumatoid arthritis (RA).  
 Jung et al. (2015) were the first to evaluate the relationship of salivary cortisol levels 
with depression, stress, and disease activity in patients with systemic lupus erythematosus 
(SLE) compared to healthy controls. Their results showed similar levels in perceived stress 
and salivary cortisol in both groups, but higher levels of alpha-amylase and depression in 
patients with SLE. Significant correlations between depression and 1) erythrocyte 
sedimentation rate (ESR) and 2) disease activity index were found. These results indicated 
autonomous nervous system (ANS) and HPA axis dysregulation in patients with SLE. 
 Harle et al. (2006) measured serum neuropeptide Y and cortisol or plasma ACTH 
levels to assess sympathetic nervous system (SNS) and HPA activities in patients with SLE or 
RA, and healthy controls. Their results showed that patients with SLE or RA had greater SNS 
activation and lesser HPA axis activation than the healthy controls. Thus, they concluded that 
an altered activity of the SNS and HPA axis is present in patients with autoimmune disease. 
 On the other hand, various studies have analyzed HPA axis regulation in patients with 
Sjögren’s syndrome (SS) by measuring salivary cortisol levels. Van der Goes et al. (2011) 
compared salivary cortisol levels during the day and ESR in patients with SLE, patients with 
(SS), and healthy persons. Their results showed that SLE and SS patients with high ESR had 
lower cortisol awakening response (CAR) than patients with low ESR. However, the authors 
concluded that HPA axis dysfunction in the patients with SLE and SS was not clear, because 
the cortisol levels were no different than those of the healthy persons. In a later study, Miller 
et al. (2012) evaluated salivary cortisol between 10 and 12 am in patients with SS and healthy 
persons, and found no differences between the two groups. 
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 Consequently, no consensus has been reached regarding HPA axis response in patients 
with autoimmune disease, because it has not been studied in many specific diseases, and 
because the findings from those studies show different directionality regarding regulation. 
Furthermore, the methods used for analyzing salivary cortisol, urine, and plasma show values 
for isolated measures of HPA axis activity. We believe that in order to gain a deeper 
understanding of the relation between psychological stress and autoimmune-disease 
aggravation, and to know better in which direction HPA regulation is being produced, it is 
essential to research HPA axis activity, by studying cortisol levels retrospectively as well as 
in the context of laboratory testing. Consequently, the objective of our investigation has been 
to study HPA axis activity between women with autoimmune disease compared to healthy 
women by analyzing salivary cortisol during the day as a current measure, and hair cortisol as 
a retrospective measure of chronic stress. For the latter, we analyze hair cortisol 
concentrations from the three preceding months and psychological stress through self-report 
measures.  
Material and methods 
Participants 
 Sixty-five women participated in this study. Thirty were healthy and had a mean age 
of 44.70 years (SD = 11.65). Thirty-five had an autoimmune disease and a mean age of 48.26 
years (SD = 9.04). Within this second group 11 women had SLE, 12 SS, and 12 systemic 
sclerosis (SSc). 
 The healthy women were recruited through posters in public institutions, newspapers, 
and local radio. The inclusion criteria were age 18–65, literate, and not presenting a physical 
or mental disease at the time of the study. Because of their potentially negative effect on 
cortisol levels (Williams et al., 2004), the exclusion criteria were: hypertension, heart disease, 
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obesity, clinical diagnosis of depression or anxiety, personality disorders, and substance use 
(i.e., amphetamines, methadone, barbiturates, or muscle relaxants). This information was 
obtained through a semi-structured interview conducted when the women called to participate 
in the study.  
 The women with autoimmune disease were recruited by medical staff from the 
Systemic Autoimmune Disease Units (Internal Medicine Service) at the Virgen de las Nieves 
University Hospital and the San Cecilio Clinical Hospital, both located in Granada, Spain. 
They were recruited during an appointment with their doctor to confirm they were not 
experiencing symptom flare up at the time of study. The inclusion criteria were age 18–65, 
literate, diagnosed according to medical diagnostic criteria with systemic lupus 
erythematosus, Sjögren’s syndrome, or systemic sclerosis; no corticosteroid treatment for a 
minimum of one year previous to the study; and no severe psychiatric disorders. The 
exclusion criteria were: obesity, clinical diagnosis of depression or anxiety, personality 
disorders, and substance use (i.e., amphetamines, methadone, barbiturates, or muscle 
relaxants). The study is focused in these diseases for they are by far more prevalent in females 
in both hospitals. In addition, these are systemic and autoimmune diseases with a common 
genetics. There considerable literature explaining common manifestations of the autoimmune 
diseases and possible therapeutic targets in adults (Kochi, 2016) and children (Li et al., 2015). 
Procedure  
 A brief interview was conducted by telephone with each woman interested in 
participating in the study to ensure they met the inclusion criteria for either the healthy group 
or the autoimmune disease group. Once accepted, the participants were provided information 
regarding the study. They then read and signed the informed consent form, which had been 
approved by both hospitals’ ethics committees and was in accordance with the 
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recommendations of the Helsinki Declaration. Subsequently, the women were interviewed, 
and then they completed the perceived stress and psychopathological symptomatology 
questionnaires. 
 All the participants were tested in the lab between Mondays to Thursdays, and they 
collected the saliva samples the next day. In this way, the salivary cortisol samples were 
collected on weekdays, not on weekends. 
 The procedure for collecting salivary cortisol samples during the day was explained to 
the participants. They were then given a kit containing 5 Salivette® tubes, a detailed 
instruction-sheet explaining sample collection and a record sheet for indicating the day and 
the time the sample was collected. We instructed them to avoid eating (neither chewing gum 
nor candy) or drinking except water and were not allowed to smoke during the half hour 
preceding each sample collection. For sample collection, they were told to introduce and soak 
the cotton swab during one minute. For example, they self-collected one salivary sample in 
the lab after the explanation, to assure they could collect the sample correctly and that the 
saliva did not have red blood cells or another contaminants element. Finally, a lock of head 
hair was cut, which upon analysis is thought to provide cortisol levels from the previous 3 
months. Two days later the participants were to deliver the salivary cortisol samples and 
record sheet to the laboratory. For assure the adherence we paid them 20 € delivered the 
samples. 
 The salivary cortisol samples of two patients with SS could not be measured because 
there was not enough saliva to analyze the cortisol levels. There were three outliers values 
from hair samples in the healthy group and two outliers from hair samples in the autoimmune 
group that were included for the analysis.  
 Instruments 
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 The questionnaires below provide meaningful covariates that were used in the 
statistical analyses of psychological measures and cortisol levels. 
Semi-structured interview: The subjects provided information on socio-demographic factors, 
daily life and sleep habits, medication, and history of psychiatric or psychological treatment. 
This information was completed with the medical history from patients with autoimmune 
diseases. 
Perceived Stress Scale (PSS) (Cohen, Kamarak, and Mermeistein, 1983; Spanish adaptation 
by Remor and Carrobles, 2001): The PSS is a self-report scale used to evaluate perceived 
stress levels and the degree to which people find their lives unpredictable, uncontrollable, or 
overwhelming (aspects that contribute to stress) over the past seven days, including the day 
the scale is administered. The PSS consists of 14 items with five response alternatives. The 
highest score corresponds to the highest perceived stress level. The Spanish version of the 
PSS (14 items) has adequate reliability (internal consistency=0.81 and test-retest=0.73), 
concurrent validity, and sensitivity (Remor, 2006). Here, we considered scores over 22 (i.e., 
the mean score for the Spanish population; Remor and Carrobles, 2001) as reflecting high 
levels of perceived stress. 
SCL-90-R Symptoms Inventory (SCL-90-R): The SCL-90-R (Derogatis, 1994; Spanish 
adaptation by Gonzalez de Rivera et al., 1988) is a self-report questionnaire that was 
developed to assess symptoms of psychopathology. It comprises 90 items with five response 
alternatives (0-4) on a Likert scale. Subjects respond according to how they have felt within 
the past seven days, including the day the inventory is administered. The inventory is scored 
and interpreted according to nine main dimensions (somatization, obsessive-compulsive 
symptoms, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid 
ideation, and psychoticism) and three global indices of psychological distress (Global 
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Severity Index [GSI], Positive Symptom Total [PST], and Positive Symptom Distress Index 
[PSDI]). This instrument demonstrates satisfactory levels of reliability and validity (De las 
Cuevas et al., 1991).  
Cortisol measures 
Measurement of cortisol during the day: Salivary cortisol sample-collection was performed 
using a Salivette® Cortisol kit (Sarstedt, Numbrecht, Germany, Ref.51.1534) that consists of 
two small tubes, one of which contains a small piece of cotton. Participants chewed the cotton 
for approximately 60 seconds and then placed it back into the same tube for analysis. Samples 
were analyzed at the San Cecilio Clinical Hospital using the electrochemiluminescence 
immunoassay “ECLIA” method. This method was designed for use in Roche Elecsys 
1010/2010 automated analyzers with the Elecsys MODULAR ANALYTICS E170 module. 
 Each participant collected five samples of salivary cortisol during one day. The first 
sample (Cortisol 1) was collected 30 minutes after waking up (while still fasting), the second 
(Cortisol 2) at +4 hours, the third (Cortisol 3) at +8 hours, the fourth (Cortisol 4) at +12 hours, 
and the fifth (Cortisol 5) at +16 hours. We asked them to write down in the record sheet the 
times of each sample collection, and set an alarm on the subjects’ phone for to ensure they 
collected the saliva samples at the appropriate time. 
Measurement of hair cortisol: Hair samples were cut with scissors from the posterior vertex 
of the head as closely to the scalp as possible by a researcher experienced with hair collection. 
Each sample consisted of approximately 150 strands of hair. The samples were then wrapped, 
labeling the scalp end in a piece of aluminum foil to protect the hair from light and humidity 
and stored in an envelope at room temperature. Later, they were sent to the Faculty of 
Pharmacy at the University of Granada where the 3 cm segments of hair most proximal to the 
scalp were analyzed (assuming an average growth rate of 1 cm/month (Wennig, 2000), a 3 cm 
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segment contains cortisol that has been deposited over approximately the last 3 months). The 
sample was washed twice with 1 ml of high performance liquid chromatography (HPLC)-
grade isopropanol, by repeated inversion for 3 minutes, using a rotator. Subsequently, the 
sample was weighed and ground to a fine powder to break up the hair’s protein matrix and 
increase the surface area for extraction using a ball mill (Bullet Blender Storm, Swedesboro 
NJ, USA). Cortisol from the interior of the hair shaft was extracted into HPLC-grade 
methanol by incubation of the sample for 72 hours at room temperature in the dark, with 
constant inversion using a rotator. After incubation, the supernatant was evaporated until 
completely dry using a vacuum evaporator (Centrivac, Heraeus, Hanau, Germany) and the 
extract was reconstituted in 150 uL of phosphate buffered saline (PBS) at pH 8.0. The 
reconstituted sample was immediately frozen at -20ºC for later analysis (Sauvé, 2007; Chen et 
al., 2013; Meyer et al., 2014). 
 The hair cortisol sample was measured using the Salivary ELISA Cortisol kit© (Alpco 
Diagnostics®, Windham, NH) as per the manufacturer’s directions with the reagent provided, 
conscious that the results from the ELISA method would be higher than those obtained 
through mass spectrometry (Slominski et al., 2015). The cross reactivity as reported by the 
manufacturer is as follows: Prednisolone 13.6%, Corticosterone 7.6%, Deoxycosticosterone 
7.2%, Progesterone 7.2%, Cortisone 6.2%, Deoxycortisol 5.6%, Prednisone 5.6% and 
Dexamethasone 1.6%. No cross-reaction was detected with DHEAS and Tetrahydrocortisone. 
 The intra- and inter-assay variations were analyzed on internal quality controls used 
for routine saliva cortisol measurement, analyzed in duplicate on ten consecutive assays. The 
intra-assay coefficients of variance were 4.4% at 11.1ng/ml and 2.6% at 54.4 ng/ml. The 
inter-assay coefficients of variance were 12.7 and 10.2%, respectively. In addition, it is 
important to note that the ELISA kit used by our group is the same one used by Russell et al. 
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(2015) in a study carried out by four leading laboratories in hair testing. In this study, four 
immunoassay methods and two liquids chromatography–mass spectrometry (LC–MS/MS) 
methods were compared by analyzing the same hair samples representing the low, 
intermediate and, high ranges of hair cortisol concentrations (HCC). The results of this study 
showed that HCC determined by the four immunoassay methods were highly and positively 
inter-correlated (r2 between 0.92 and 0.97; all P <0.0001) in all comparisons of individual 
laboratories. Additionally, each laboratory’s HCC immunoassay had significant positive 
correlations (r2 between 0.88 and 0.97; all P <0.0001) with each of the two LC–MS/MS 
methods, which produced practically identical results.  
 The hair cortisol levels were expressed in pg/mg values as in the studies of Sauvé et al. 
(2007) and Henley et al. (2013). Sauvé et al. (2007) used Alpco ELISA kit and they 
established one reference range of 1.7 - 153.2 pg/mg (log-transformed) in people without 
obesity. As well, Henley et al. (2013) used the same kit and the results showed a median hair 
cortisol level (range) of 116 (26 - 204) pg/mg for healthy persons and 177 (93 - 273) pg/mg 
for individuals reporting stress. 
Statistical analyses 
 Student’s t-tests were conducted to control for differences between both groups (the 
autoimmune disease group and the healthy group) with regard to socio-demographic variables 
(age and education level) and psychological variables (SLC-90-R and PSS). 
 A mixed 2 × 5 analysis of covariance (ANCOVA) was then conducted to check for 
statistically significant differences between both groups regarding cortisol levels during the 
day. The first factor includes two levels (healthy group and autoimmune disease group) 
between the independent groups. The second was a repeated-measures within-subject factor at 
five time points: (Cortisol 1) collected 30 minutes after waking up (while still fasting), 
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(Cortisol 2) at +4 hours, (Cortisol 3) at +8 hours, (Cortisol 4) at +12 hours, and (Cortisol 5) at 
+16 hours. The Greenhouse-Geisser Correction was applied in the repeated-measures 
analyses. The anxiety and somatization subscales of the SLC-90-R were included as 
covariates. Student’s t-tests were conducted to determine whether there were differences in 
saliva cortisol samples between both groups. 
 Further, the AUCg was measured in all participants, which provided information 
regarding the changes occurring during observation of the dependent variable (salivary 
cortisol levels). The AUCg was calculated using the trapezoid formula from Pruessner et al. 
(2003). An ANCOVA was then run to check for significant differences in AUCg between the 
healthy group and the autoimmune disease group. The anxiety and somatization subscales of 
the SLC-90-R were included as covariates. 
 Hair cortisol concentrations were natural log (ln, base e) transformed to normalize 
values. An ANCOVA was then run to check for significant differences in hair cortisol 
between the healthy group and the autoimmune disease group. The anxiety and somatization 
subscales of the SLC-90-R were included as covariates. 
 Pearson correlation analyses were used to examine cross-sectional associations among 
hair cortisol concentrations and the total amount of salivary cortisol produced (AUCg) and 
hair cortisol concentrations and the five time points of salivary cortisol during de day.  
 All data were analyzed with SPSS version 21.  
Results 
Sample description 
 Table 1 presents the participants’ socio-demographic and psychological variables. 
There were no group differences in socio-demographic, perceived stress, and 
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psychopathological symptomatology variables, with the exception of the anxiety and 
somatization subscales of the SCL-90-R. The autoimmune disease group shows higher scores 
than the healthy group on the somatization subscale and lower scores on the anxiety subscale. 
There were no significant differences between years of illness and the three diseases: SLE 
(10.34 ± 9.24 years), SS (5.04 ± 4.85 years), and SSc (9.17 ± 5.95 years). The average years 
of disease in the autoimmune group was 8.12 ± 7.03. 
INSERT TABLE 1 
Cortisol during the day 
 The statistical analyses show that there was no significant time × group interaction 
effect, however, there were statistically significant differences in AUCg cortisol levels (F 
(1,59) = 4,209.031; p ≤ 0.001): the autoimmune disease group exhibited higher levels (M = 
21,578.92 ± 7,936.25 nmol/L) than the healthy group (M = 15.18 ± 7.90 nmol/L). Figure 1 
shows the  AUCg salivary cortisol values.  
 There were significant differences at the Cortisol 2 (t = -2.949; p = 0.005), Cortisol 3 
(t = -2.395; p = 0.020), and Cortisol 5 (t = -3.081; p = 0.003) collections, where the 
autoimmune disease group showed higher levels than the healthy group. Data cortisol levels 
at different times during the day are shown in Table 2.   
INSERT FIGURE 1 
INSERT TABLE 2 
Hair cortisol 
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 The results revealed statistically significant differences between groups with regard to 
hair cortisol concentrations (F(1,63) = 5.542; p = 0.022), with  the autoimmune disease group 
exhibited higher concentrations than the healthy group (Figure 2). 
INSERT FIGURE 2 
 There were three outliers values from hair samples in the healthy group with a 
concentrations of 499.72 pg/mg, 365.43 pm/mg, and 27.59 pg/mg. The two outliers from hair 
samples in the autoimmune group were of 24.05 pg/mg and 30.10 pg/mg.  
 There was a positive correlation between the hair cortisol levels and AUCg levels (r = 
0.402; p = 0.001) and a positive correlation between the hair cortisol levels and the Cortisol 5 
samples (r = 0.268; p = 0.034). 
  
 Discussion 
 The objective of our research was to study HPA axis activity among women with 
autoimmune disease compared to healthy women on two levels: by analyzing the salivary 
cortisol levels during one day as a measure of current stress, and hair cortisol as a 
retrospective measure of chronic stress. For the latter, we analyzed hair cortisol measures 
containing concentrations from hair samples approximating the three preceding months, and 
psychological stress levels through self-report measures. 
 All socio-demographic and psychological variables were similar for both groups, with 
the exception of the somatization subscale, in which the autoimmune disease group showed 
higher scores, foreseeable when comparing healthy persons to others with disease. 
Differences on the anxiety subscale were also found, reflecting higher scores for the healthy 
group. Nevertheless, even though both somatization and anxiety affect AUCg levels and the 
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healthy group was experiencing more anxiety, AUCg levels were still significantly higher in 
the autoimmune disease group. 
 However, tests of HPA axis activity indicated significant differences in AUCg, with 
higher levels observed in the autoimmune disease group than in the healthy group. These 
results indicate HPA axis hyper-activation in patients with autoimmune disease that could be 
caused by the alteration of the immune system. Thus, we cannot confirm that autoimmune 
patients will have lower levels of cortisol than the healthy population. One example of this is 
a study by Straub et al. (2010), in which patients with RA showed HPA axis activation similar 
to that of healthy persons. According to Straub, this led to chronic activation of the 
sympathetic nervous system in the autoimmune disease patients, which acted as a 
compensation mechanism between the two axes: because these patients were experiencing 
inflammation, HPA axis activation could not resemble that of healthy persons. This produces 
a desynchronization between both axes.  
 Similarly, Jung et al. (2015) found that patients with SLE had higher levels of alpha-
amylase than healthy controls. Nevertheless, differences in salivary cortisol levels were not 
found between patients with SLE and healthy controls. However, unlike our study, the 
patients with SLE who participated in that study were undergoing corticosteroid treatment, 
and that could affect the results and how HPA axis activation was interpreted in those SLE 
patients. The differences in results between both studies could be explained by the fact that 
our study included patients with other autoimmune diseases, in addition to patients with SLE, 
and none of our patients had received corticosteroid treatment for a minimum of one year 
preceding the study, so as to guarantee elimination of corticosteroids in the patients’ systems 
and the hyper atrophy of the adrenal glands that results from corticosteroid use (Ruiz-Arruza 
et al., 2014).  
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 Van der Goes et al. (2011) also evaluated salivary cortisol in patients with primary SS 
and patients with SLE. The study found that the ESR predicted HPA axis activation in those 
patients, thus patients with elevated ESR had lower CAR than patients with low ESR. Since 
our patients did not suffered intense inflammation (as shown by the absence of corticoid 
treatment), and although we did not evaluate these variables, we think that they could explain 
the differences we found in cortisol levels during the day between the autoimmune disease 
and the healthy group.  
 On other hand, the results of higher saliva cortisol levels in the Cortisol 2, Cortisol 3, 
and Cortisol 5 samples of the day collected in autoimmune diseases group seems like a lack of 
circadian rhythm in cortisol levels across the day. Chung, Son, and Kim (2011) revised 
studies where patients with abnormal HPA axis activity showed circadian rhythm related 
symptoms. They concluded that this had implications and risks factors in the health and 
disease. 
 Currently, all studies of this axis have focused on cortisol in blood, saliva or urine, 
measures that provide scores from minutes, hours or days. To date, however, HPA axis 
activity has not been studied retrospectively through hair cortisol in persons with SLE, SS and 
SSc versus healthy people. This is a technique that provides stable cortisol readings 
unaffected by individual and environmental characteristics, study procedures (Wolfram et al., 
2013), the time of day (Adam et al., 2006), and food consumption (Gibson et al., 1999) 
maintained during months.    
  Regarding hair cortisol levels accumulated during the preceding three months, the 
results revealed the same as those for salivary cortisol levels AUCg; namely, that women with 
autoimmune disease showed higher cortisol levels than healthy women. The significant 
correlation between both measures confirms these results.  
CORTISOL LEVELS AND AUTOIMMUNE DISEASES                                                                                18 
 
 
 Our results concerning salivary and hair cortisol indicate that the autoimmune disease 
group presents higher HPA axis activity. The HPA axis behaves similarly in both the long and 
short-term, as women with autoimmune disease have greater HPA axis activity than healthy 
women. This fact could also be due to the time that they have been suffering the illness and 
elevated blood interleukin-6 (IL-6) levels. Mastorakos et al. (2013) associated elevated IL-6 
levels with elevated HPA axis activity of patients with sarcoidosis. Furthermore, Fujio et al. 
(2016) investigated the influence of inteleukin-6 levels on the HPA axis after onset of 
corticoids treatment in patients with autoimmune diseases and they found positive correlation 
between levels of IL-6 and basal cortisol.  
 Our findings are similar to those from studies included in the review by Meyer and 
Novak (2012), in which long-term HPA axis activity measured by hair cortisol levels and 
short-term HPA axis activity measured by salivary cortisol are related under certain 
conditions. In this regard, ours is the first study to include salivary and hair cortisol measures 
for evaluating and comparing HPA axis activity in women with autoimmune disease who are 
not undergoing corticosteroid treatment with healthy women.  
 There are some limitations to our study. It would be interesting to evaluate a larger 
sample of patients with autoimmune disease with a broader scope of autoimmune pathologies, 
as well as other hormones, such as alpha-amylase, that are directly involved in regulating the 
HPA axis and sympathetic adrenomedullary system, because both are key components in the 
response to stress and carry out an important modulator role in the immune system. 
Additionally, it is recommended that saliva samples should be collected during the day at 
approximately the same time for all participants (difficult due to differences in awakening 
hours and bedtime). It is further recommended to collect saliva samples over two consecutive 
days and calculate the means at each sampling time. 
CORTISOL LEVELS AND AUTOIMMUNE DISEASES                                                                                19 
 
 
Conclusions 
 Both higher cortisol hair concentrations and hormonal production indicate that women 
with autoimmune disease have increased long and short-term HPA axis activity than healthy 
women. Anxiety and somatization levels could be predictor variables of a greater response to 
daily stress.  This could be caused by dysregulation of HPA axis in patients with autoimmune 
disease.. These findings provide novel information on HPA axis behavior in persons with 
autoimmune disease.  
Lay summary 
 This study examines the HPA axis activity in healthy women and women with 
autoimmune diseases (systemic lupus erythematosus, Sjögren’s syndrome and systemic 
sclerosis) by analyzing salivary cortisol, hair cortisol levels, and self-report measures of 
stress. We found that autoimmune disease group scored higher on the somatization subscale 
SCL-90-R, the area under curve for salivary cortisol levels during the day, and hair cortisol 
concentrations. This could suggest greater short and long-term HPA axis activity in women 
with autoimmune disease than in healthy women. 
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Table 1. Means and standard deviations (SD) of socio-demographic and psychological 
variables for the participants in both groups. 
 
 
Healthy Group 
(n = 30) 
Mean ± SD 
Autoimmune Group 
(n = 35) 
Mean ± SD 
 
     t 
 
   p 
 
Age (years) 
 
44.70 ± 11.65 
 
48.26 ± 9.04 
  
 1.92 
 
  0.17 
Education (years) 15.33 ± 3.57 14.14 ± 3.79  1.68   0.20 
Perceived Stress Scale 25.47 ± 5.93 26.74 ± 9.93  0.38   0.54 
Symptom Checklist SCL-90-R 
Somatization 51.73 ± 27.48 74.70 ± 22.67 13.18  0.001** 
Obsessions and 
compulsions 
78.43 ± 21.97 78.70 ± 24.84  0.002   0.96 
Interpersonal sensitivity 71.33 ± 28.21 67.06 ± 33.65  0.29   0.59 
Depression 66.77 ± 28.46 63.61 ± 32.39  0.17   0.68 
Anxiety 71.07 ± 20.75 63.21 ± 31.93  4.08   0.048* 
Hostility 65.97 ± 22.85 56.91 ± 33.64  1.53   0.22 
Phobic Anxiety 48.37 ± 38.77 48.88 ± 38.31  0.003   0.96 
Paranoia 65.27 ± 32.75 54.70 ± 36.67  1.44   0.23 
Psychoticism 69.43 ± 32.74 59.97 ± 32.38  1.33   0.25 
 t: t-student value; *p ≤ 0.05. ** p ≤ 0.01  
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Table 2. Means and standard deviations (SD) of salivary cortisol during the day  
Cortisol samples (nmol/L) Healthy Group (n = 30 ) 
M ± SD 
Autoimmune Group (n = 33) 
M ± SD 
Cortisol 1 (30’ after waking 
up) 
15.56 ± 7.89 18.15 ± 8.74 
Cortisol 2 (at +4 hours)  6.10 ± 3.21 9.03 ± 4.60 
Cortisol 3 (at +8 hours)  5.49 ± 3.33 7.61 ± 3.70 
Cortisol 4 (at +12 hours)  5.27 ± 4.67 6.47 ± 4.44 
Cortisol 5 (at +16 hours) 3.89 ± 3.77 6.75 ± 3.55 
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Figure 1. AUCg levels from the salivary cortisol during the day for the healthy group and the 
autoimmune disease group. 
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Figure 2. Hair cortisol levels from the previous three months for the healthy group and the 
autoimmune disease group. 
 
 
 
 
 
 
 
 
